Based on this hypothesis and an observed association between plasma markers and mortality in patients with ARDS [26], IL-6 was used as a surrogate endpoint in a recent randomized controlled trial that evaluated the safety of preventive antiviral treatment in ICU patients [16]. Here, IL6 is linked to acute respiratory distress syndrome.